Recordati Industria Chimica e Farmaceutica Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Rob Koremans
Geschäftsführender
€2.2m
Gesamtvergütung
Prozentsatz des Geschäftsführergehalts | 27.4% |
Amtszeit als Geschäftsführer | 2.5yrs |
Eigentum des Geschäftsführers | n/a |
Durchschnittliche Amtszeit des Managements | 3.5yrs |
Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.8yrs |
Jüngste Management Updates
Recent updates
Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30Analyse der Geschäftsführervergütung
Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
---|---|---|---|
Mar 31 2024 | n/a | n/a | €389m |
Dec 31 2023 | n/a | n/a | €389m |
Sep 30 2023 | n/a | n/a | €375m |
Jun 30 2023 | n/a | n/a | €389m |
Mar 31 2023 | n/a | n/a | €340m |
Dec 31 2022 | €2m | €590k | €312m |
Sep 30 2022 | n/a | n/a | €331m |
Jun 30 2022 | n/a | n/a | €330m |
Mar 31 2022 | n/a | n/a | €393m |
Dec 31 2021 | €154k | n/a | €386m |
Vergütung im Vergleich zum Markt: RobDie Gesamtvergütung ($USD2.31M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Italian ($USD4.03M).
Entschädigung vs. Einkommen: RobDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Rob Koremans (62 yo)
2.5yrs
Amtszeit
€2,154,000
Vergütung
Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...
Führungsteam
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
CEO & Director | 2.5yrs | €2.15m | keine Daten | |
Group CFO & Executive Director | 4.6yrs | €1.11m | keine Daten | |
Executive Director | no data | keine Daten | keine Daten | |
Executive Director | no data | keine Daten | keine Daten | |
Executive Director | no data | keine Daten | keine Daten | |
VP & Head of Investor Relations | less than a year | keine Daten | keine Daten | |
Group Chief Legal Officer | 1.2yrs | keine Daten | keine Daten | |
Group Communications Director | no data | keine Daten | keine Daten | |
Executive VP of Corporate Development | 7.8yrs | keine Daten | keine Daten | |
Group Chief People & Culture Officer | less than a year | keine Daten | keine Daten | |
Executive Vice President of Group Industrial Operations | 9.2yrs | keine Daten | keine Daten | |
Chief Medical Officer | 5.4yrs | keine Daten | keine Daten |
3.5yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: RECDas Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
CEO & Director | 2.5yrs | €2.15m | keine Daten | |
Group CFO & Executive Director | 2.4yrs | €1.11m | keine Daten | |
Executive Director | 5.5yrs | keine Daten | keine Daten | |
Executive Director | 5.5yrs | keine Daten | keine Daten | |
Executive Director | 4.2yrs | keine Daten | keine Daten | |
Non-Executive Chairman | 26.2yrs | €352.00k | keine Daten | |
Independent Non-Executive Director | 4.2yrs | €77.00k | keine Daten | |
Lead Independent Director | 10.2yrs | €98.00k | keine Daten | |
Independent Director | 2.4yrs | €61.00k | keine Daten | |
Chairman of Statutory Auditor Board | 7.2yrs | keine Daten | keine Daten | |
Independent Non-Executive Director | 5.3yrs | €82.00k | keine Daten | |
Non-Executive Vice Chairman | 4.2yrs | €60.00k | keine Daten |
4.8yrs
Durchschnittliche Betriebszugehörigkeit
54.5yo
Durchschnittliches Alter
Erfahrener Vorstand: RECDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).